Juno Therapeutics Inc. (JUNO) Rose To A New High After Purchased By Celgene

Juno Therapeutics Inc. (JUNO) announced Monday morning that it has agreed to be acquired by Celgene Corp. (CELG) for $87 per share in cash, approximately $9 billion.

from RTT - Before the Bell http://ift.tt/2rsHis0
via IFTTT